← Back to Clinical Trials
Recruiting NCT06597864

NCT06597864 Seven-step Phenomenological Psychotherapy for Self-disorder - a Pilot Study

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06597864
Status Recruiting
Phase
Sponsor Oslo University Hospital
Condition Psychosis;Schizophrenic
Study Type INTERVENTIONAL
Enrollment 8 participants
Start Date 2024-10-17
Primary Completion 2026-03-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 39 Years
Study Type INTERVENTIONAL
Interventions
Seven-step phenomenological psychotherapy for self-disorders

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 8 participants in total. It began in 2024-10-17 with a primary completion date of 2026-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this clinical pilot study is to learn how adults with schizophrenia or other non-affective psychotic disorders or psychosis risk syndromes experience a novel psychotherapeutic treatment for self-disorders. The study has a qualitative, phenomenological research design. After end of treatment, the participants are interviewed about the experience of the treatment. This include how the participants liked it, if it was experienced as helpful and useful, and changes in self-experience and experience of relations to others and the world.

Eligibility Criteria

Inclusion Criteria: * Clinical diagnoses in the ICD-10-CM Code range, i.e. schizophrenia, schizotypal, delusional, and other non-mood psychotic disorders. First diagnosed no more than 3 years ago. * Or Psychosis risk syndrome as defined in the Structured Interview of Psychosis-Risk Syndromes (SIPS) (McGlashan, Walsh, \& Woods, 2010) * Present with anomalous self-experiences, as confirmed by the Screen Questionnaire for EASE (SQuEASE-6) (Møller, 2018) * Motivated to explore and work with anomalous self-experiences in psychotherapy Exclusion Criteria: * Severe, ongoing psychosis * Severe, ongoing drug abuse * IQ\<70 * Poor Norwegian language profiency

Contact & Investigator

Central Contact

Tor Gunnar Værnes, Dr.philos.

✉ uxvrnt@ous-hf.no

📞 0047 92 45 56 78

Principal Investigator

Tor Gunnar Værnes, Dr.philos.

PRINCIPAL INVESTIGATOR

Oslo University Hospital, Early Intervention in Psychosis Advisory Unit for South-East Norway

Frequently Asked Questions

Who can join the NCT06597864 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 39 Years, studying Psychosis;Schizophrenic. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06597864 currently recruiting?

Yes, NCT06597864 is actively recruiting participants. Contact the research team at uxvrnt@ous-hf.no for enrollment information.

Where is the NCT06597864 trial being conducted?

This trial is being conducted at Sandvika, Norway, Oslo, Norway.

Who is sponsoring the NCT06597864 clinical trial?

NCT06597864 is sponsored by Oslo University Hospital. The principal investigator is Tor Gunnar Værnes, Dr.philos. at Oslo University Hospital, Early Intervention in Psychosis Advisory Unit for South-East Norway. The trial plans to enroll 8 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology